ibidi Awarded with the Export Award Bavaria: Special Edition 2021

02-Dec-2021 - For its excellent crisis strategy during the pandemic, ibidi GmbH has been awarded the Export Award Bavaria 2021: Special Edition 2021, in the category, "Successful Order Processing in Corona Times." The award, which has been presented since 2007 to small- and medium-sized companies that work ...

Axiogenesis and Metrion Biosciences announce stem cell collaboration

Collaboration to develop human iPSC-derived cardiomyocytes and neurons for translational drug discovery

08-Nov-2016 - Axiogenesis AG, a preclinical biotechnology company specialising in the development and production of induced pluripotent stem cell (iPSC)-derived cells and tissues for preclinical applications, and Metrion Biosciences Ltd, the specialist ion channel CRO, have signed a collaboration agreement to ...

Sigma Life Science Announces Scientific Advisory Board to drive ADME/Tox program

Board to Provide Counsel on New Solutions for Pre-clinical Testing with Sigma’s CompoZr® Zinc Finger Nuclease (ZFN) Technology

14-Jun-2011 - Sigma Life Science, the biological products and services research business of Sigma-Aldrich Corporation, announced the formation of an ADME/Toxicology Scientific Advisory Board (ADME/Tox SAB) in an effort to help drive development of new cell-based assays using the Company's innovative CompoZr ...

Max Planck Innovation awards license for actin marker LifeAct

Max Planck Innovation and ibidi sign license agreement for cytoskeleton research

28-Jul-2010 - Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for LifeAct to ibidi GmbH, a provider of cell analysis products, located in Martinsried near Munich. The novel peptide allows for actin, an important protein, to be made ...

ibidi establishes partnership with Seahorse Bioscience

05-Feb-2009 - ibidi GmbH announced a partnership with Seahorse Bioscience, Inc. of Billerica; Main, USA. Under the terms of the agreement ibidi will exclusively distribute the products of Seahorse Bioscience in Germany and Austria. With this partnership ibidi further strengthens its position as a service ...

FivePrime Reports Discovery of IL-34

13-May-2008 - Science, researchers at Five Prime Therapeutics, Inc. report the discovery of Interleukin34, a novel cytokine, as well as the identification of an IL-34 receptor. "This work is a textbook example of how our platform enables us to make important new discoveries with secreted proteins, even in ...

Roche and ACEA enter exclusive world-wide agreement

Roche Applied Science acquires innovative key technology for cell-analysis

19-Nov-2007 - Roche and ACEA Biosciences Inc. announced that they have entered into an exclusive agreement for the development, supply and distribution for ACEA Bioscience's real-time cell assay technology. Under the terms of the agreement, RAS will exclusively market systems for real-time cell analysis, based ...

amaxa to Co-ordinate Collaboration to Develop High-throughput Devices for Primary Cell Transfection

04-Jul-2007 - amaxa AG has announced that it will co-ordinate a European collaboration of eight partners to develop devices for ultra high-throughput delivery and screening of primary cells, for use in the study of immunological, neuronal and liver disorders, for example. The collaboration has been granted ...

ITI Life Sciences signs commercialisation licence agreements with Edinburgh Instruments and Almac Sciences (Scotland) Ltd

01-Mar-2007 - ITI Life Sciences announced the signing of two Commercialisation Licence agreements based on intellectual assets created during ITI Life Sciences' Fluorescence Lifetime Assay Programme, using fluorescence lifetime for 3-D cell-based assays and other applications. The first licence, signed with ...

Scripps Research Scientists: Compounds Show Significant Promise Against Botulinum Neurotoxins

09-Feb-2007 - Scientists at The Scripps Research Institute and the University of Wisconsin have identified two small molecules with promising activity against neurotoxins produced by the Clostridium botulinum. Because of the high cost and limited applicability of currently available treatments, the newly ...